State of Practice: A Report from the Inaugural SNIS Neurointerventional Oncology Summit

Over the past 25-years, progress in the treatment of central nervous system (CNS) tumors has been limited and outcomes for malignancies such as glioblastoma and diffuse intrinsic pontine glioma remain dismal. There has been great interest in harnessing endovascular neurointerventional techniques and to use the cerebral vasculature as a route for therapeutic delivery in neuro-oncology. Several selective intra-arterial clinical trials are currently underway targeting a range of CNS tumors with different therapeutic agents. The Society of NeuroInterventional Surgery (SNIS) convened the inaugural Neurointerventional Oncology Summit which was held on April 26-27, 2024, at the University of Texas MD Anderson Cancer Center in Houston, Texas. The group consisted of neuro-interventionists, neurosurgeons, neuro-oncologists, neuroradiologists, basic scientists and industry representatives who are current practitioners in this emerging space. We report the current state of practice and our efforts to develop an organizational platform to treat patients suffering from CNS cancers and to advance research in this emerging field. Endovascular surgical neuro-oncology is an emerging clinical endeavor which aims to provide novel therapeutic options for CNS cancers. Novel therapeutic agents including yttrium-90, oncolytic viruses and cellular immunotherapy are being tested as intraarterial therapy. Technological advances in imaging modalities, selective methods of blood brain barrier opening, and devices and catheters will aid advancement of the field. Multi-disciplinary cooperation and collaboration will be integral to the success of this endeavor. BBB = blood brain barrier; CAR = chimeric antigen receptor; DIPG = diffuse intrinsic pontine glioma; ESIA = endovascular selective intra-arterial; ESSIA = endovascular super-selective intra-arterial; FUS = focused ultrasound; GBM = glioblastoma; MSC-D24 = delta 24 oncolytic virus in mesenchymal stem cell; NK = natural killer; Y-90 = yttrium-90.